Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Daiichi Sankyo

Generated: March 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,232,401

« Back to Dashboard

Title:4-oxoquinoline compound and use thereof as HIV integrase inhibitor
Abstract: An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formula [I] ##STR00001## wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.
Inventor(s): Satoh; Motohide (Takatsuki, JP), Kawakami; Hiroshi (Takatsuki, JP), Itoh; Yoshiharu (Takatsuki, JP), Shinkai; Hisashi (Takatsuki, JP), Motomura; Takahisa (Takatsuki, JP), Aramaki; Hisateru (Takatsuki, JP), Matsuzaki; Yuji (Takatsuki, JP), Watanabe; Wataru (Takatsuki, JP), Wamaki; Shuichi (Takatsuki, JP)
Assignee: Japan Tobacco Inc. (Tokyo, JP)
Filing Date:Jun 05, 2006
Application Number:11/446,128
Claims:1. A compound selected from the group of formulas (a)-(d): ##STR00346## or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound according to claim 1, or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

3. A method for the treatment of an HIV infectious disease comprising administering to a mammal the compound of claim 1, or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.

4. A compound of the formula: ##STR00347##

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Chinese Patent Office
Queensland Health
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.